Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy

Table 5 Association between combined bilirubin levels and response to treatment

Combined bilirubin levels1	Objective response2		Simple analysis		Multiple analysis3
	n	Yes (%)	OR (95%CI)	P value	OR (95%CI)	P value
Group 1	24	4 (16.7)	1.000 (ref.)		1.000 (ref.)
Group 2	83	29 (34.9)	2.685 (0.838-8.604)	0.096	3.215 (0.918-11.255)	0.068
Group 3	13	9 (69.2)	11.250 (2.286-55.367)	0.003	16.001 (2.802-91.371)	0.002

¹Group 1: individuals with total bilirubin > 13.0 and unconjugated bilirubin > 4.1; Group 2: individuals with total bilirubin ≤ 13.0 and unconjugated bilirubin > 4.1; Group 3: individuals with total bilirubin ≤ 13.0 and unconjugated bilirubin ≤ 4.1;

²Yes, partial and complete response;

³Multiple analyses were adjusted for age, sex, KPS, histology, primary tumor site and treatment regimen; KPS: Karnofsky performance status.